• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

How IBM is using deep learning to detect diabetic eye disease

April 21, 2017 By Sarah Faulkner

IBMIBM’s deep learning technology can detect and classify the severity of diabetic retinopathy with 86% accuracy, according to new research. The diagnostic tool could help doctors and physicians better understand disease progression and determine treatment, IBM said.

The company’s technology was trained to identify lesions using more than 35,000 eye images. It can classify the severity of disease across 5 levels: no diabetic retinopathy, mild, moderate, severe or proliferative diabetic retinopathy. The method combines deep learning, convolutional neural networks and dictionary-based learning to incorporate disease-specific pathologies.

“The alarming projections of the number of patients with diabetic retinopathy have major implications for the health system. The loss of vision from the condition can impose an enormous burden on the individual, including a loss of capacity to work and the need for intensive community support,” principal investigator Dr. Peter van Wijngaarden said in prepared remarks. “To substantially reduce the number of people unnecessarily losing vision from diabetic eye disease, there is a real need for innovation to improve effective screening of those who are at risk to enable early sight-saving treatment.”

Traditionally, clinicians diagnose diabetic retinopathy by monitoring patients with regular screenings. The process is time-intensive and subjective, IBM said.

Computer vision methods to diagnose and classify lesions in 20 seconds could help clinicians screen a greater number of patients.

“Recent advancements in deep learning and image analytics technologies are showing significant promise in the potential to help solve some of the greatest health challenges we face today,” VP and lab director of IBM Research Australia, Dr. Joanna Batstone, said. “Automated and highly accurate DR screening methods have the potential to help doctors screen far more patients than currently possible.”

Filed Under: Big Data, Diabetes, Diagnostics, Featured, Optical/Ophthalmic, Research & Development Tagged With: IBM

IN CASE YOU MISSED IT

  • Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
  • Study finds MannKind inhaled insulin safe, effective for children
  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS